Profound delayed thrombocytopenia presenting 16 days after Abciximab (Reopro®) administration

Platelets

Volumn 22, Issue 4, 2011, Pages 302-304

  Webb, G J ^a   Swinburn, J M A ^a   Grech, H ^a  

^a ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

Author keywords

Abciximab; delayed; platelets; thrombocytopenia

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; AMIODARONE; BISOPROLOL; CLOPIDOGREL; DALTEPARIN; DEXAMETHASONE; GLYCERYL TRINITRATE; HEPARIN; IMMUNOGLOBULIN; OPIATE; STEROID;

AGED; ANAMNESIS; AORTA BALLOON; ARTICLE; BARE METAL STENT; BLOOD TRANSFUSION; CASE REPORT; ELECTROCARDIOGRAM; HEART ATRIUM FIBRILLATION; HUMAN; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT DEPRESSION; THORAX PAIN; THROMBOCYTOPENIA;

AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BLOOD TRANSFUSION, AUTOLOGOUS; DEXAMETHASONE; ERYTHROCYTE TRANSFUSION; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET TRANSFUSION; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 79956017183     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2010.518324     Document Type: Article

References (15)

1. Shadoff N, Valett N, Bates E, Galeana A, Knopf W, Shaftel J, Bender M, Aversano T, Raqueno J, Gurbel P. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330(14):956-961.
2. Berkowitz SD, Sane DC, Sigmon KN, Shavender JH, Harrington RA, Tcheng JE, Topol EJ, Califf RM. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. J Am Coll Cardiol 1998;32(2):311-319. (Pubitemid 28396477)
3. Tcheng JE, Kereiakes DJ, Lincoff AM, George BS, Kleiman N, Sane DC, Cines DB, Jordan RE, Mascelli MA, Langrall MA and others. Abciximab readministration: Results of the ReoPro Readministration Registry. Circulation 2001;104(8): 870-875. (Pubitemid 32778035)
4. Merlini PA, Rossi M, Menozzi A, Buratti S, Brennan DM, Moliterno DJ, Topol EJ, Ardissino D. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Circulation 2004;109(18):2203-2206. (Pubitemid 38625397)
5. Aster RH. Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest 2005;127(2 suppl):53S-59S. (Pubitemid 40224082)
6. Nowakowski K, Rogers J, Nelson G, Gunalingam B. Abciximab-induced thrombocytopenia: Management of bleeding in the setting of recent coronary stents. J Interv Cardiol 2008;21(1):100-105. (Pubitemid 351178392)
7. Lown JA, Hughes AS, Cannell P. Prolonged profound abciximab associated immune thrombocytopenia complicated by transient multispecific platelet antibodies. Heart 2004; 90(9):e55.
8. Bertrand OF, De Larochelliere R, Rodes-Cabau J, Proulx G, Gleeton O, Nguyen CM, Dery JP, Barbeau G, Noel B, Larose E and others. A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation. Circulation 2006;114(24): 2636-2643. (Pubitemid 44967347)
9. McCorry RB, Johnston P. Fatal delayed thrombocytopenia following abciximab therapy. J Invasive Cardiol 2006; 18(6):E173-174. (Pubitemid 44680987)
10. Makoni SN. Acute profound thrombocytopenia following angioplasty: The dilemma in the management and a review of the literature. Heart 2001;86(6):E18.
11. Jang IK, Hursting MJ. When heparins promote thrombosis: Review of heparin-induced thrombocytopenia. Circulation 2005;111(20):2671-2683. (Pubitemid 40740868)
12. Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR, McCarthy LJ, Sarode R, Hatfield AJ, Feldman MD and others. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000;342(24): 1773-1177.
13. Sane DC, Damaraju LV, Topol EJ, Cabot CF, Mascelli MA, Harrington RA, Simoons ML, Califf RM, CAPTURE EE, EPISTENT Study Groups. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol 2000;36(1):75-83. (Pubitemid 30466115)
14. Llevadot J, Coulter SA, Giugliano RP. A practical approach to the diagnosis and management of thrombocytopenia associated with glycoprotein IIb/IIIa receptor inhibitors. J Thromb Thrombolysis 2000;9(2):175-180. (Pubitemid 30093589)
15. Huxtable LM, Tafreshi MJ, Rakkar ANS. Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptor antagonists. Am J Cardiol 2006;97(3):426-429. (Pubitemid 43133064)